Teva Pharmaceutical Industries Limited American Depositary Shares - TEVA STOCK NEWS

Teva Pharmaceuticals announced the launch of the IMPACT-TD Scale, a standardized assessment for measuring the burden of tardive dyskinesia (TD) beyond just movement severity. Developed in collaboration with the TD community, the scale incorporates insights from patients, caregivers, and healthcare providers. It categorizes TD's impact into various areas such as social, psychological, and vocational aspects, aiming to enhance patient dialogue and comprehensive understanding. With 780,000 affected individuals in the U.S., this tool is expected to improve monitoring and overall management of TD, following a consensus published in the Journal of Clinical Psychiatry in November 2022.

Teva Pharmaceuticals has received FDA approval for AUSTEDO XR (deutetrabenazine) extended-release tablets, a once-daily treatment for tardive dyskinesia (TD) and chorea associated with Huntington’s disease (HD). This new formulation is available in 6 mg, 12 mg, and 24 mg strengths, providing a convenient option that may reduce pill burden for patients. AUSTEDO XR is the only VMAT2 inhibitor with long-term efficacy data for these conditions, offering sustained treatment options. Teva aims to facilitate patient adherence with this innovation, expected to be available in the U.S. later this year.

Teva Pharmaceuticals has settled Florida's price-fixing claims, agreeing to pay $6.73 million. The settlement resolves the state's claims, allowing Teva to focus on compliance and business operations. This marks Teva's fifth settlement regarding price-fixing allegations, with payments reflecting the state's population share. The amount falls within estimated provisions made in Q3 2022. Teva maintains its commitment to quality and antitrust compliance while continuing discussions with other states to settle similar claims.

Teva Pharmaceutical Industries Ltd. reported a net loss of $2.35 billion for 2022, with a diluted loss per share of $2.12. Total revenues for the year were $14.9 billion, a 6% decrease from 2021, attributed to lower sales of COPAXONE and respiratory products. For Q4 2022, revenues were $3.9 billion, while GAAP diluted EPS stood at $(1.10). The company anticipates revenues in 2023 to range between $14.8 - $15.4 billion, with adjusted EBITDA expected at $4.5 - $4.9 billion. Positive momentum was noted in innovative products like AUSTEDO and AJOVY, which drove significant growth.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) announced that its greenhouse gas (GHG) emission reduction targets have been approved by the Science Based Targets initiative (SBTi). These targets aim for a 46% reduction in absolute scope 1 and 2 GHG emissions by 2030 and a 25% reduction in absolute scope 3 emissions. The initiative aligns with a 1.5°C climate pathway. Teva's sustainable financing strategy includes a $5 billion sustainability-linked bond, the largest in its sector. The company emphasizes the connection between health and environmental sustainability as part of its corporate social responsibility.

Teva Pharmaceutical Industries Ltd. (NYSE:TEVA) will release its Q4 and full year 2022 financial results and 2023 financial guidance on February 8, 2023, at 7:00 a.m. ET. A conference call will follow at 8:00 a.m. ET. Interested participants can register here. A replay will be available within 24 hours on Teva's website.

Teva Pharmaceuticals has moved forward with a nationwide settlement aimed at resolving opioid-related claims, having secured participation from 48 of 50 U.S. states. The agreement, reached in collaboration with a working group of States’ Attorneys General, does not include an admission of wrongdoing. Teva believes the settlement is in the best interest of impacted communities and allows the company to concentrate on its patients. The process for subdivisions of the states to join the settlement will start soon, reflecting positive engagement from the states.

The FDA has accepted the Biologics License Application (BLA) for AVT04, a proposed biosimilar to Stelara® (ustekinumab), developed by Alvotech and Teva Pharmaceuticals. The regulatory review is expected to complete in the second half of 2023. AVT04 aims to treat inflammatory conditions and has shown therapeutic equivalence in clinical trials. This partnership was formed in August 2020 to commercialize Alvotech’s biosimilar products in the U.S. Both companies are focused on expanding access to cost-effective biosimilar treatments.

Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) will present at the 41^st Annual J.P. Morgan Healthcare Conference on January 11, 2023, at 10:30 A.M. Pacific Time (1:30 P.M. Eastern Time). Interested parties can access the live webcast on Teva's Investor Relations website, with an archived version available within 24 hours and accessible for up to 30 days. Teva has over 3,500 products in its portfolio, serving around 200 million patients globally every day.